Uncovering Parkinson’s subtypes: insights from Victoria Catterson’s MJFF webinar

In June, Victoria Catterson, VP of Data Science Research at BioSymetrics (a Renovaro company), was honoured by the Michael J. Fox Foundation (MJFF) as one of 13 global Data Community Innovators for 2025–2026. The recognition highlights her leadership in open science and her contributions to MJFF’s Community of Practice, particularly in advancing data-driven research using the Parkinson’s Progressive Markers Initiative (PPMI) dataset.

As part of her new role, Victoria delivered a webinar in July, offering a comprehensive walkthrough of a machine learning pipeline developed at BioSymetrics to identify phenotypic subtypes of Parkinson’s disease. Her presentation covered data preprocessing, feature engineering across multiple clinical domains, unsupervised clustering, and model evaluation – balancing statistical rigour with the interpretability needed for clinical insight.

She also shared practical tips drawn from real-world analysis of the PPMI dataset, including strategies for handling noisy inputs, reducing dimensionality, and improving reproducibility. The full recording is available here: https://zenodo.org/records/15936672.

Full speed ahead: progress on LUMINA and glioblastoma projects

Renovaro Cube is moving full steam ahead across multiple fronts in precision healthcare. In July, the Cube team joined forces with Flomics, Oncodia AB, and Uppsala University to kick off the LUMINA Project – a collaborative initiative aimed at advancing cancer diagnostics. The consortium aligned on workstreams and timelines and agreed to begin one month earlier than scheduled, underscoring the shared commitment to accelerate progress.

In parallel, Cube’s glioblastoma project continues to show strong technical momentum. The team is developing an AI-powered clinical decision-support tool by integrating tumour-educated platelet RNA with MRI imaging to enhance disease monitoring and treatment decisions. Nebul compute environments are now live for deep learning training, RNA preprocessing workflows are being finalised, and the platelet RNA pipeline is under expert review with UMC Amsterdam – all laying the foundation for more accurate, personalized care.

Landmark study confirms therapeutic potential of Renovaro’s dendritic cell cancer therapy platform

Renovaro Biosciences has published landmark preclinical results in Vaccines, highlighting the efficacy of its next-generation dendritic cell (DC) therapy platform against pancreatic cancer. The study demonstrated that engineered DCs – developed from CD34⁺ stem cells and modified to express CD93, CD40L, and CXCL13 – induced significant tumour regression and strong immune activation in humanized mouse models. This work validates the scientific foundation of Renovaro’s allogeneic, off-the-shelf immunotherapy approach, designed to overcome the immunosuppressive barriers that often hinder treatment in solid tumours.

In these models, tumour volume was reduced by as much as 81.7%. The therapy triggered robust expansion of CD4⁺, CD8⁺, and NK cells in both blood and tumour tissues, and induced antigen-specific cytotoxicity against pancreatic cancer cells while sparing healthy ones. By leveraging CD34⁺ stem cells from healthy donors, this platform enables scalable production and cryopreservation of engineered DCs – a key step toward clinical translation. Renovaro plans to expand preclinical development to additional tumour types and explore combination strategies with checkpoint inhibitors and radioligand therapies, in line with its broader goal to personalize immune-enhancing treatments across a range of cancers.

The publication also honours the late Dr. Anahid Jewett, whose collaboration and immunological expertise were critical to the study’s success. Her contributions reflect the deep scientific rigour underpinning this work. Renovaro views this platform as a foundation for its growing pipeline and a springboard for AI-driven antigen discovery – a step toward more precise and durable cancer therapies. The full paper is available here: https://www.mdpi.com/2076-393X/13/7/749.

Join us as we drive machine learning precision medicine forward

There’s much more ahead – join us as we push the boundaries of machine learning precision medicine, especially in oncology and neurology. Follow and tag us on LinkedIn, X (formerly Twitter), Bluesky, and Threads.

An AI patent to advance drug discovery and diagnostics

We at Renovaro have secured a new U.S. patent for BioSymetrics’ (a Renovaro company) AI framework, advancing our mission to modernize drug discovery and diagnostics. The patent protects novel methods for harmonizing fragmented biomedical data – including genomics, imaging, and clinical records – into a unified structure for predictive modelling. This addresses a longstanding barrier in pharmaceutical R&D: translating disparate data into actionable insights.

Our patented methods are designed for distributed and parallel computing, enabling scalable, real-time analytics across a range of biomedical applications. Combined with our 2022 patent on machine learning pipeline optimization, this new IP further strengthens the foundation of our end-to-end AI platform – enhancing its value for commercial partners and supporting innovation in personalized medicine.

Read more: https://ir.renovarogroup.com/news/news-details/2025/Renovaro-Secures-Key-U-S--Patent-to-Strengthen-AI-Driven-Drug-Discovery-and-Diagnostics-Platform/default.aspx

Victoria Catterson, Data Community Innovator for the Michael J. Fox Foundation

Victoria Catterson, VP of Data Science Research at BioSymetrics (a Renovaro company), was named a Data Community Innovator by the Michael J. Fox Foundation (MJFF) for her leadership within the Parkinson’s research community and her active contributions to the MJFF Community of Practice. She will join 12 other global researchers in sharing expertise on data analysis and engagement with the Parkinson’s Progressive Markers Initiative (PPMI) dataset. Her appointment reflects our commitment to collaborative science and underscores our dedication to advancing open, data-driven neurological research.

Renovaro is planning a webinar this July highlighting Victoria’s work with the MJFF – stay tuned for details.

Read more: https://www.renovarogroup.com/article/victoria-catterson-data-community-innovator-mjff

Renovaro at BIO 2025

At BIO 2025 in Boston, our team – including Gabe Musso, Chief Scientific Officer of BioSymetrics (a Renovaro company) – joined industry peers to showcase our Oncology and Neurology programs. Oncology remains competitive but focused, with strong interest in biomarker-driven, translational approaches. Neurology stood out as a rising priority, especially in non-opioid pain – a key focus of our KCC2 program. We were also encouraged by unexpected interest in applying neuroscience innovations to companion-animal health, highlighting potential directions for platform expansion.

Read more: https://www.renovarogroup.com/article/reflections-from-bio-2025

Join us as we drive AI-driven precision medicine forward

There’s much more ahead – join us as we push the boundaries of AI-driven precision medicine, especially in Oncology and Neurology. Follow and tag us on LinkedIn, X (formerly Twitter), Bluesky, and Threads.

‍

LOS ANGELES, June 30, 2025 (Newswire.com) - Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents, including weaponized substances like Sarin. The platform has been integrated into Renovaro's Defense Countermeasures Program, marking a strategic entry into the dual-use biotechnology and biodefense sector. Renovaro's platform is anchored by advanced data preprocessing coupled with in vivo toxicity testing, creating a robust, end-to-end discovery pipeline bolstered by their recently announced patent, "Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions". This IP milestone expands the company's foundational portfolio, further protecting its machine learning infrastructure for multi-modal biomedical data integration and predictive analytics-core to its scalable drug discovery and diagnostics business.

"This is a defining moment for Renovaro as we extend the value of our AI platform from traditional life sciences into national security," said David Weinstein, CEO of Renovaro. "With a growing patent estate and entry into the defense market, we are unlocking new revenue channels and expanding the commercial potential of our core technologies."

Value Drivers:

• Strengthened IP Portfolio: New patent adds to Renovaro's protected methods for real-time, reproducible analytics across distributed computing environments.
• Defense Market Entry: Renovaro's AI-zebrafish platform enables high-throughput, physiologically relevant screening for CNS-active neurotoxins.
• Commercial Expansion: Platform is highly adaptable to pharma applications, rare diseases, and clinical trial acceleration.
• Differentiated AI Platform: Combines proprietary model optimization, advanced feature selection, and biological automation.
• New Revenue Opportunities: Supports partnerships, licensing, and government grants/contracts in both biomedical and national security domains.

The AI-based platform which uses an inexpensive zebrafish-based model for validation of neurotoxicity predictions, delivers rapid, automated screening of over 1,000 compounds per week, significantly outpacing traditional animal models. It captures behavioural, cardiovascular, and muscular responses to neuroactive chemicals, enabling ML-driven compound triage and mechanism of action prediction. This capability is vital for both commercial CNS drug discovery and defense applications involving neurotoxic exposure.

"Investors increasingly seek companies with platforms that are both scientifically robust and commercially scalable," said Weinstein. "Our ability to serve large markets in biopharma and national security - each with deep funding pools and urgent unmet needs - creates a unique, de-risked growth trajectory."

About Renovaro Inc.

Renovaro Inc. (NASDAQ: RENB) is building category-defining AI-driven platforms for precision medicine, diagnostics, and biodefense. Its proprietary technologies transform complex biomedical data into predictive insights, enabling faster discovery, greater accuracy, and strategic partnerships across the life sciences and government sectors.

Contact:

Nathen Fuentes
Chief Financial Officer
investors@renovaro.com
www.renovarogroup.com

Original press release: https://www.newswire.com/news/renovao-launches-ai-based-neurotoxin-countermeasure-initiative-addressing

LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) – Renovaro Inc. (NASDAQ: RENB), an AI-driven precision medicine company that leverages AI/ML platforms to improve outcomes for cancer and neurologically challenged patients, today announced it has launched Augusta, a Precision Neurology Platform for patient stratification, biomarker discovery, drug discovery, and validation. Augusta is focused on neurology where diagnosis and treatment have historically lagged. Built on the company’s Renovaro Cube and Elion platforms and recently validated through work in Parkinson’s Disease and epilepsy, the platform combines multimodal data analytics with proprietary in silico screening to identify biomarkers and therapeutics in a fraction of the time of conventional methods.

Neurological disorders remain among the most difficult to diagnose and treat due to heterogeneity in symptoms, unclear disease boundaries, and limited biomarkers. Augusta addresses these challenges through:

• Data Preprocessing: Augusta is the first biomedical-specific machine learning (ML) platform to perform fast, effective data pre-processing. It uses a patented process to enable optimization of all decision points in data processing, reducing bias and improving results for drug discovery/development, diagnostics, and precision medicine.
• Phenoclustering: Advanced clustering of patient-level phenotypic and clinical data to define biologically and clinically meaningful subgroups.
• Biomarker identification: Fusion of multimodal data pipelines with predictive analytics to derive precise, actionable biomarkers. Biomarkers include clinical features, as well as molecular features identified using proprietary transformer models designed to detect mutations and epigenetic alterations.
• In silico screening: Proprietary models built on generative frameworks that predict the effect of disrupting thousands of genes in silico, reducing the number of experiments and animals used.
• Closed loop validation: Initial validation in CRISPR modified zebrafish empowered by proprietary computer vision models provides fast confirmation of gene and small molecule effects on brain development and behaviour, while simultaneously providing readouts on unwanted toxicities in specific genetic backgrounds.
  

Unlike black-box approaches, the Augusta platform emphasizes interpretability, clinical alignment, and rigorous benchmarking. Augusta’s modular infrastructure enables plug-and-play model evaluation, including for large language models (LLMs) conditioned using proprietary knowledge graphs. This supports continuous innovation while maintaining clinical and experimental robustness.

“The Augusta platform is about validation,” said David Weinstein, Renovaro CEO. “We’re setting a new bar for how AI can be responsibly and effectively deployed in clinical and experimental settings.”

The efficacy of this approach has already been demonstrated in Parkinson’s Disease, where phenoclustering identified novel and highly predictable patient subgroups with unique clinical characteristics and biomarkers, and in epilepsy, where novel lead compounds were identified specifically addressing patient populations with rare genetic mutations.

With a strong foundation in Parkinson’s disease and epilepsy, Renovaro plans to expand its precision neurology efforts into additional neurological disorders. Strategic partnerships with academic medical centres and life sciences companies are currently being discussed.

About Renovaro

Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit www.renovarogroup.com.

Forward-Looking Statements

This press release contains statements by Renovaro Biosciences Inc. (“Renovaro”, “we”, “us”, “our” or the “Company”) that are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, our prospects, plans, business strategy and expected financial and operational results. You can identify these statements by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would”, ”could”, ”project”, ”plan”, “potential”, ”designed”, “seek”, “target”, variations of these terms, the negatives of such terms and similar expressions. These statements are based on certain assumptions that we have made in light of our experience in our industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. You should not rely on forward-looking statements because our actual results may differ materially from those indicated by forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: the success or efficacy of our pipeline, platform and fundraising; our ability to successfully integrate business that we have acquired, including BioSymetrics, or that we may acquire; our ability to achieve the benefits that we expect to realize as a result of our acquisitions, including BioSymetrics; and those other risks and uncertainties discussed in the reports we have filed with the Securities and Exchange Commission (the “SEC”), such as our most recent Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date the statements were made. We do not undertake any obligation to update forward-looking information, except to the extent required by applicable law.

Investor Relations

Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us

For media inquiries, please contact:

karen@renovarocube.com